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Panels of chemically-modified heparin
polysaccharides and natural heparan sulfate
saccharides both exhibit diﬀerences in binding
to Slit and Robo, as well as variation between
protein binding and cellular activity†
Yassir A. Ahmed,ab Edwin A. Yates,a Diana J. Moss,c Markus A. Loeven,a
Sadaf-Ahmahni Hussain,d Erhard Hohenester,d Jeremy E. Turnbull‡a and
Andrew K. Powell‡*ae
Heparin/heparan sulfate (HS) glycosaminoglycans are required for Slit–Robo cellular responses. Evidence
exists for interactions between each combination of Slit, Robo and heparin/HS and for formation of a
ternary complex. Heparin/HS are complex mixtures displaying extensive structural diversity. The relevance of this
diversity has been studied to a limited extent using a few select chemically-modified heparins as models of HS
diversity. Here we extend these studies by parallel screening of structurally diverse panels of eight chemically-
modified heparin polysaccharides and numerous natural HS oligosaccharide chromatographic fractions for
binding to both Drosophila Slit and Robo N-terminal domains and for activation of a chick retina axon response
to the Slit fragment. Both the polysaccharides and oligosaccharide fractions displayed variability in binding and
cellular activity that could not be attributed solely to increasing sulfation, extending evidence for the importance
of structural diversity to natural HS as well as model modified heparins. They also displayed differences in their
interactions with Slit compared to Robo, with Robo preferring compounds with higher sulfation. Furthermore,
the patterns of cellular activity across compounds were different to those for binding to each protein,
suggesting that biological outcomes are selectively determined in a subtle manner that does not simply reflect
the sum of the separate interactions of heparin/HS with Slit and Robo.
Introduction
Slits are a family of secreted, multidomain glycoproteins which
are ligands for the transmembrane immunoglobulin (Ig) super-
family proteins called roundabouts (Robos).1,2 Slit–Robo signalling
was originally identified as being important in axon guidance3,4 but
has since been found to have numerous biological roles5–7 and
some association with human pathologies.8
Several experiments have suggested that cellular Slit activity
requires heparan sulfate proteoglycans (HSPGs) as a co-receptor.
In particular, ex vivo studies showed that human (h) Slit2 activity
on rodent forebrain explants or Xenopus retinal axon growth cones
can be eliminated by enzymatic degradation of cell-surface heparan
sulfate (HS) chains.9–11 In addition, through genetic studies, Slit
and Robo have also been associated with enzymes involved in HS
biosynthesis, or the core proteins of HSPGs in C. elegans, Drosophila
and mice.12–17 HS or heparin (a natural, highly sulfated variant of
HS which is more readily-available, pharmaceutically important
and often used as a proxy for HS) interact with both Slit and
Robo.10,18–21 Heparin also affects binding of Slit to Robo which
suggests formation of a ternary complex.10
HS and heparin are highly heterogeneous glycosaminoglycans
(GAGs) that possess a repeating disaccharide unit consisting
of uronic acid (b-D-glucuronic acid or a-L-iduronic acid) and
a-D-glucosamine. The uronic acid can possess a hydroxyl or sulfate
group at position-2, whilst glucosamine can exhibit either group at
position-6 and position-3. Glucosamine can also display an N-acetyl,
N-sulfonamido or free amino group at position-2 (Fig. 1).
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This structural variation in disaccharide sulfation and epi-
merisation has been shown to influence protein binding and
regulation of protein activity.22 However, only limited information
exists regarding the eﬀect of this diversity on the Slit/Robo system.
Such an eﬀect has been investigated for a few protein systems
using chemically-modified heparin polysaccharides and (less
commonly) chromatographic fractions of tissue-derived HS oligo-
saccharides which display variable sulfation.23,24 To date, Slit and
Robo interactions have been studied separately and using only a
few chemically-modified heparin polysaccharides that exhibit
very limited diversity.19,20,25 Here we investigate the implications
of HS structural diversity for the Slit/Robo system using a broad
panel of eight structurally-diverse chemically-modified heparins,
as model polysaccharides, in combination with a panel of
numerous saccharide chromatographic fractions generated from
tissue HS. This enables us to assess the consequences of diversity
within natural HS as well as chemically-modified heparin model
compounds and also to assess both polysaccharides and oligo-
saccharides that may diﬀer in physical properties and biochemical
activities.21,23 We screened their abilities to interact with N-terminal
fragments of both Drosophila (d) Slit and dRobo through using
parallel protein binding assays, enabling direct protein comparison
for the first time. Furthermore, using an ex vivo chick retinal axon
collapse assay, we screened their ability to promote the cellular
activity of the dSlit fragment. The data suggest structural selectivity
and clear diﬀerences between the profiles for binding to the
diﬀerent proteins and for protein binding and promotion of
cellular activity.
Results and discussion
dRobo Ig1–5 and dSlit D1–4 exhibit subtly different
interactions with chemically-modified heparin polysaccharides
The importance of structural diversity within heparin/HS mixtures
for the Slit/Robo system has only been investigated previously in
separate studies, using a few select chemically-modified heparins of
limited diversity with either hSlit proteins19,25 or a short hRobo1
fragment.20 To compare the eﬀect of diversity on binding to Slit
and Robo in parallel, we investigated in vitro binding of a broad
panel of eight chemically-modifiedheparins tobothdSlit anddRobo.
Chemicalmodification involves the introduction of systemic varia-
tion in sulfation pattern compared with the unmodified parental
heparin (Table 1 and Fig. 1). The resulting variants are structurally
well-defined (ESI† Page S3) and known to exhibit distinct con-
formations and activities.26 We used proteins from Drosophila
which expresses only a single Slit. DSlit has N-terminal and
C-terminal heparin binding sites (Fig. 2), with N-terminal LRR
domains having been shown to be suﬃcient for Robo binding and
bioactivity.10 For simplicity, only the leucine-rich repeat (LRR)
domains of dSlit were used. LRR domains D1–D4 were selected
(Fig. 2) because, although D1 and D2 alone have been shown
to bind to heparin (and D2 to bind Robo and exhibit bioactivity),
D1–4 has a higher apparent affinity for heparin.10 Drosophila
expresses three Robos and we used dRobo. Similar to dSlit, the
N-terminal (Ig) domains of dRobo are sufficient for dSlit or heparin
binding (Fig. 2). Again, although only dRobo Ig1–2 was found to be
required for interactions with heparin or Slit, Ig1–5 was used (Fig. 2)
as it has a slightly higher apparent affinity for heparin.10,27
Dose–response experiments showed that dSlit D1–4 required
higher concentrations compared with dRobo Ig1–5-Fc for binding
to immobilised heparin oligosaccharides from a size exclusion
chromatography (SEC) fraction (Fig. 3A), suggesting differential
protein binding, with dSlit D1–4 binding being weaker. This was
Fig. 1 Schematic of the structure of heparin/HS disaccharide repeats.
Depicted are a-L-iduronate and a-D-glucosamine. R1 = H, acetyl or SO3

and R2 = H or SO3
. a-L-iduronic acid is formed from b-D-glucuronic acid
through epimerization of the carboxyl group. * indicates sites where there
is a major increase in sulfation during oversulfation of heparin.
Table 1 Characteristics of chemically-modified heparin compounds.
I and A represent iduronate and glucosamine, respectively. 2S, 2OH, 6S,
6OH, NS, NAc represent sulfate (S), hydroxyl (OH) and acetyl substitutions
at positions 2, 6 and N of iduronate or glucosamine
Compound
Predominant
disaccharide repeat Short-hand
Average sulfation
per disaccharide
1 I2SA
6S
NS Heparin 3
2 I2OHA
6S
NS 2-OH 2
3 I2SA
6OH
NS 6-OH 2
4 I2SA
6S
NAc N-Ac 2
5 I2OHA
6S
NAc 2-OH/N-Ac 1
6 I2SA
6OH
NAc 6-OH/N-Ac 1
7 I2OHA
6OH
NS 2-OH/6-OH 1
8 I2OHA
6OH
NAc 2-OH/6-OH/N-Ac 0
9 I2S,3SA
6S
3S,NS Oversulfated (OS) 5
Fig. 2 Schematic showing the domain structure of dSlit and dRobo. (A) dSlit
showing D1–4 leucine-rich repeat (LRR), epidermal growth factor-like (EGF)
and laminin G-like (LG) domains along with the C-terminal cystine-knot (CT).
(B) dRobo showing immunoglobulin-like (Ig1–5), fibronectin type 3-like
(FN3); transmembrane (TM) and conserved cytosolic motifs (CC0–3)
domains. N represents N-terminus. Black colour filling represents dRobo
and dSlit binding domains. Horizontal lines show HS-binding fragments.
Brackets show protein fragments used in this study.
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confirmed using a competition ELISA (where binding of poly-
saccharides is assessed through their ability to compete with the
surface immobilised saccharide28), in which parental unmodified
heparin (compound 1) was found to bind dSlit D1–4 less strongly
(i.e. requiring higher concentrations of heparin: EC50 B 7-fold
higher) than dRobo Ig1–5-Fc (Fig. 3Bi and Ci).
Furthermore, heparins modified at a single position within
disaccharide repeats (compounds 2–4) showed lower binding
compared to parental heparin, but the reduction in binding
was less pronounced for dSlit D1–4 than for dRobo Ig1–5-Fc
(Fig. 3Bi and Ci). Heparins desulfated at two or three positions
within disaccharide repeats (compounds 5–8) uniformly showed
relatively very poor binding to both dSlit D1–4 and dRobo Ig1–5-Fc
(Fig. 3Bii and Cii). Finally, oversulfated (OS) heparin (compound 9)
possessing increased sulfation at two additional positions
within the disaccharide repeats to parental unmodified heparin
(see Table 1 and Fig. 1), also displayed reduced binding to dSlit
D1–4 and dRobo Ig1–5-Fc compared with unmodified heparin,
which was to a slightly greater extent for the dRobo fragment
(Fig. 3Biii and Ciii).
Overall, these data suggest that binding of heparin and
chemically-modified heparins to dSlit and dRobo N-terminal
domains diﬀers slightly: dRobo domains bind more strongly
than dSlit to heparin and this binding is aﬀected more by both
desulfation and oversulfation of heparin. The reduction of
polysaccharide binding to the proteins by oversulfation, as well
as desulfation, of heparin suggests a degree of structural
selectivity involving a particular range of sulfation or factors
other than the extent of sulfation. Although it is possible that
the diﬀerence in binding between his6-cmyc-dSlit D1–4 and
dRobo Ig1–5-Fc reflect the Fc moiety causing dimerization of
dRobo Ig1–5-Fc, which in turn results in an avidity effect on
binding to the heparin variants, it is likely that the receptor
domains can act independently as part of a dimeric Fc fusion
protein, hence avidity effects may not occur.28
Comparison of our new data on binding of Slit with that of
previous studies indicates subtle diﬀerences. We observed that
binding of dSlit D1–4 to heparin was reduced almost equally by
alteration at either of the 2, 6, or N-positions. In contrast, using
only two variants (N-desulfated and N,O-desulfated heparins
that are likely to possess positive charges on free amino groups
at pH 7.4 of the binding assays), others found that O-sulfate,
but not N-sulfate groups are required for modified heparins to
compete with the interaction of rat glypican-1-Fc with full
length hSlit2.19 Changes made selectively at the N-position in
our work involved N-desulfation/re-N-acetylation hence the
compounds do not possess similar modification, thus properties,
at the N-position. Alternatively, using four variants, including one
with N-modification similar to one of our variants, Shipp and
Hsieh-Wilson25 observed that N-, 6-O- and 2-O-modified heparins
bound to full length hSlit2 in decreasing order, with the latter
exhibiting negligible binding. Our data suggest less difference
between the binding abilities of these variants. This subtle
discrepancy may reflect the use of different Slit proteins and
binding assays. The full length hSlit2 protein used by Shipp and
Hsieh-Wilson has two binding sites for heparin of different
apparent affinities, with the C-terminal domain having a higher
apparent affinity than the D1–4 region. Furthermore, Shipp and
Hsieh-Wilson used glycan array methodology with limited
heparin spotting concentrations (50, 25 and 15 mM) and which
also depends on passive immobilisation of the polysaccharides
on the array surface that may alter the apparent affinities of
variants.25 In contrast, our study used a dSlit protein fragment
containing only the N-terminal LRR domains (which have been
shown to be sufficient for biological activity) and a competition
assay with a wider range of chemically-modified heparin structures
across a wide range of concentrations, equivalent to B80 nM to
300 mM.
In terms of Robo, our observation in the present study that
single modification at the diﬀerent major positions within
disaccharide repeats substantially reduced dRobo Ig1–5-Fc
binding (with loss of 6-O sulfates having the largest effect) is
in agreement with previous work using hRobo1 Ig1–2.20 However,
comparison is again made difficult by the use of different compe-
tition assays, proteins and heparin variants (e.g. N-desulfated
rather than N-desulfated/re-N-acetylated). Overall, this comparison
of studies demonstrates the importance of using parallel studies,
that involve the same assay format and carbohydrate compounds,
when comparing the structural features in heparin that are
involved in binding to both Slit and Robo.
Chemically-modified heparin polysaccharides diﬀerentially
regulate dSlit D1–4 cellular activity.
Previously, the activities of full length or fragments of hSlit2
have been assessed using mouse, rat, frog and chick ex vivo
explant assays.9–11,29,30 To our knowledge, no ex vivo Slit activity
assay exists for Drosophila to match the dRobo used in the
binding assays. Therefore, to assess the effect of diversity in
regulation of dSlit D1–4 cellular activity, we developed a convenient
ex vivo assay employing axons from chick retina,31 which is similar
to the assay used previously with hSlit2.29,30 There is a single Slit
gene in invertebrates and three in vertebrates.2 In contrast, there
are three Robo genes in Drosophila, Xenopus and chick and four
in mammals.32,33 Slits from different species have 41–44%
homology.2 DSlit or a dSlit D2 fragment have been shown to
bind both rat Robo1 and 2 and to induce a human cell
response, respectively, suggesting conservation of function
across vertebrates and invertebrates.2,27 It is known that retina
from chick embryos express Robo1 and Robo2.29 Sequence
alignment showed 44 and 48% identity between Ig1–5 domains
of dRobo and chick (c)Robo1 and 2, respectively (ESI,† Pages S4
and S5). However, it has been shown previously that Robo
Ig1 possesses the key determinants for binding to Slit and
heparin.10,27,34 Higher identities were calculated between Ig1 of
dRobo with Ig1 of cRobo1 (58%) and 2 (57%).
Addition of dSlit D1–4 in PBS to retinal axons causedB77%
collapse of growth cones compared to B15% for PBS alone
indicating that the protein was biologically active (Fig. 4A).
Removal of endogenous HS from the axons using heparinases
substantially reduced the growth cone collapse activity of dSlit
D1–4 (Fig. 4A). Addition of the protein in the presence of exogenous
heparin fully restored activity on heparinase-treated growth
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Fig. 3 dSlit D1–4 and dRobo Ig1–5-Fc interact differently with heparin and chemically-modified heparins. (A) Binding of different concentrations of
his6-cmyc-dSlit D1–4 and dRobo Ig1–5-Fc to a nitrous acid generated heparin 10-mer SEC fraction, surface-immobilised through biotinylation and
streptavidin capture. Binding was determined using an ELISA and absorbance values shown are the mean of triplicates and error bars represent the
standard deviation. Data are representative of three separate experiments. Binding of (B) his6-cmyc-dSlit D1–4 and (C) dRobo Ig1–5-IgG1Fc fusion
protein to varying concentrations of soluble chemically-modified heparins (Table 1) determined by inhibition of protein binding to an immobilized
B10-mer heparin saccharide fraction using a competition ELISA. (i) Compound 1 (heparin), 2 (2-OH), 3 (6-OH), 4 (N-Ac), (ii) compound 1 (heparin),
5 (2-OH/N-Ac), 6 (6-OH/N-Ac), 7 (2-OH/6-OH), 8 (2-OH/6-OH/N-Ac) and (iii) compound 1 (heparin) and 9 (OS). % binding values shown represent
means of triplicate wells containing competitor relative to means of triplicate wells lacking competitor and error bars represent the % combined standard
deviation. All calculations were performed as described in Experimental procedures. Data are representative of four separate experiments.
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cones (Fig. 4A). Having established that removal of endogenous HS
from chick retinal axons using heparinases prevented dSlit D1–4
activity, which could be rescued by addition of exogenous heparin,
we determined the relative rescue activities of chemically-modified
heparins. Addition of dSlit D1–4 alongside heparins modified at
single positions within the disaccharide repeats (compounds 2–4),
restored growth cone collapse activity to similar level (B75–80%) to
parental unmodified heparin (compound 1: B82%), thus placing
these variants with unmodified heparin in a high activity group
(Fig. 4B). In contrast, heparins modified at two or three positions
within their disaccharide repeats (compounds 5–8), exhibited a
much lower level of rescue (B20–30% collapse), thus placing these
variants in a low activity group (Fig. 4B). This lower activity was
similar to that of dSlit D1–4 without addition of any polysaccharide
(B20% collapse) (Fig. 4B). OS heparin (compound 9) fell between the
high and low activity groups (B50% collapse) clearly indicating that
additional sulfation is not optimal for promoting activity (Fig. 4B).
Overall the data demonstrate that sulfation levels in these
relatively homogenously modified heparins regulate their abilities
to control the biological response of chick retinal axons to dSlit
D1–4. Similar to protein binding, the reduction of polysaccharide
activity by oversulfation, as well as desulfation, of heparin suggests a
degree of structural selectivity involving a particular range of sulfa-
tion or factors other than the extent of sulfation. Addition or removal
of sulfates at two or more positions in the regular disaccharide
repeats of modified heparins had a substantial deleterious effect
similar to that observed on dSlit D1–4 or dRobo Ig1–5-Fc binding.
Modification of heparin at a single position within disaccharide
repeats, however, had little effect on cellular activity, in contrast to
larger effects observed on binding to the individual proteins.
As observed for protein binding, our results are not entirely
in agreement with previous observations. Firstly, Shipp and
Hsieh-Wilson demonstrated varied eﬀects of modification at a
single position within the disaccharide repeats of heparin on
hSlit2 cellular activity.25 In this case, the diﬀerence in results
may be due to use of diﬀerent cellular assays or Slit proteins.
Others have also reported eﬀects of modification on in vivo activi-
ties suspected to be linked with Slit–Robo signalling. Firstly,
2- and 6-O desulfation and to a lesser extent N-desulfation/N-re-
acetylation were found to affect in vivo Xenopus axon guidance.35
Secondly, HS 2-O-sulfotransferase and HS 6-O-sulfotransferase-1
knockout mice (exhibiting either altered 2-O or 6-O sulfation) have
altered axon guidance phenotypes shown to be associated with Slit
function.16,36 However for these more complex in vivo assays other
proteins may also be involved preventing direct comparison with
our ex vivo Slit cellular activity assay. Collectively, this suggests the
need for caution to avoid over-simplistic interpretation or compar-
ison of different binding or activity datasets as the experimental
context influences the detail of the results.
Generation of structurally diverse HS saccharide
chromatographic fractions
In order to explore the eﬀect of structural diversity within natural
HS on the Slit–Robo system, we next investigated protein binding
and activity using tissue-derived HS. As HS chains exhibit exten-
sive structural diversity and are potentially multi-dentate for
protein binding,23 we generated libraries of oligosaccharides by
chromatographic separation of saccharide mixtures produced by
partial heparinase III digestion of porcine mucosal HS (PMHS).24
It was shown previously that a B10-mer heparin saccharide
fraction, generated by sequential size exclusion chromatography
(SEC) and strong anion exchange (SAX)-HPLC, was able to form a
ternary complex with dSlit D2 and dRobo Ig1–2.10 We therefore
focussed on generating B8-mer and B10-mer fractions from
PMHS.24 SEC was used to separate saccharides based upon
hydrodynamic volume (Fig. 5A), which equates approximately
to differences in saccharide length. PMHSB8-mer andB10-mer
fractions were further separated based upon sulfation using
SAX-HPLC at pH B 3 (Fig. 5B and C). Fractions eluting from the
SAX columnatdifferentsalt concentrationsmainly reflectsaccharides
Fig. 4 Chemically-modified heparins divide into groups with high, medium
or low abilities to support dSlit D1–4 cellular activity. Slices of chick retina
were treated ex vivo with (A) PBS, his6-cmyc-dSlit D1–4, heparinase I, II and
III then his6-cmyc-dSlit D1–4 and heparinase I, II and III then his6-cmyc-
dSlit D1–4 with exogenous heparin, (B) heparinase I, II, III then his6-cmyc-
dSlit D1–4 in the presence or absence of chemically-modified heparins
(Table 1): compound 1 (heparin), 2 (2-OH), 3 (6-OH), 4 (N-Ac), 5 (2-OH/
N-Ac), 6 (6-OH/N-Ac), 7 (2-OH/6-OH), 8 (2-OH/6-OH/N-Ac) and 9 (OS).
Collapsed and uncollapsed growth cones were counted in blind conditions
across several pieces of retina for B100 growth cones and the % of
collapsed growth cones calculated. Values shown are the mean % of
collapsed growth cones calculated from three groups of retinal pieces and
error bars represent the standard deviation for % values. Data are repre-
sentative of two separate experiments.
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possessing differential sulfation,24 hence a range ofmajor saccharide
fractions were selected across the gradients to screen for protein
binding and cellular activity (Fig. 5B and C).
PMHS saccharide fractions possess diﬀerential protein binding
and cellular activity
Screening of SAX-HPLC saccharide fractions in the competi-
tion ELISA for binding to dSlit D1–4 and dRobo Ig1–5-Fc
indicated they possessed differential abilities (Fig. 6A and B).
Fig. 5 Generation of saccharide chromatographic fractions. PMHS was
partially digested with heparinase III and saccharide mixtures separated by
(A) SEC. Fractions from SEC that contain (B) B8-mer and (C) B10-mer
saccharides were then further separated by SAX-HPLC. Fractions across
selected peaks were broadly estimated to contain HS/heparin oligo-
saccharides displaying increasing degrees of polymerization (shown by
even integers). Pooling is shown by horizontal lines beneath peaks. SAX
sub-fractions in underlined bold correspond to those used in assays.
Chromatography elution profiles were reproducible across multiple runs.
Fig. 6 PMHS saccharides possess diﬀerential abilities to bind dSlit D1–4
or dRobo Ig1–5-Fc and promote dSlit D1–4 cellular activity. PMHS
B8-mer and B10-mer SAX-HPLC fractions were screened for binding
to (A) his6-cmyc-dSlit D1–4 and (B) dRobo Ig1–5-IgG1Fc fusion protein
using a competition ELISA. % binding values shown represent means of
triplicate wells containing competitor relative to means of triplicate wells
lacking competitor and error bars represent the % combined standard
deviation calculated as described in Experimental procedures. Control
represents protein binding to a surface lacking immobilised biotinylated
heparin saccharides. Data are representative of four separate experiments.
Fractions were also screened for their ability to rescue (C) His6-cmyc-
dSlit D1–4 ex vivo chick retinal axon growth cone collapse following
treatment with heparinases I–III. Collapsed and uncollapsed growth
cones were counted in blind conditions across several pieces of retina
forB100 growth cones and the % of collapsed growth cones calculated.
Values shown are the mean % of collapsed growth cones calculated
from three groups of retinal pieces and error bars represent the
standard deviation for % values. Data are representative of two separate
experiments.
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Interestingly, fraction 10I, which elutes at a relatively low salt
concentration (B0.75 M, Fig. 5C) indicating moderate sulfation,
had a uniquely strong ability to bind dSlit D1–4 (B70% relative
binding, Fig. 6A). In marked contrast to dSlit D1–4, dRobo Ig1–5-Fc
bound best to fraction 8F (B35% relative binding, Fig. 6B). This
fraction is particularly interesting as it eluted from the SAX column
at the lowest relative salt concentration (B0.3M) (Fig. 5B) indicating
low sulfation. All the other fractions exhibited low relative binding
(o20%: Fig. 6A and B).
We next investigated the ability of fractions to promote dSlit
D1–4 chick growth cone collapse activity. Similar to protein
binding, the fractions had differential bioactivities (Fig. 6C).
Again only a few had strong activities whilst others were similar
to the residual 30% collapse exhibited in the absence of
saccharides as a control. Fractions 10I and 8F, which had also
been found to bind well to dSlit D1–4 or dRobo Ig1–5, respectively
(Fig. 6A and B), exhibited the highest (B75%) and next highest
(B60%) activities (Fig. 6C). Interestingly, fractions 10F and 10S,
which did not bind strongly to either dSlit D1–4 or dRobo Ig1–5-Fc
(Fig. 6A and B) had medium growth cone collapse activity
(B50 and B45%, Fig. 6C). Despite possessing similar activities,
these latter fractions also elute from the SAX column at different
salt concentrations (0.7 M and 0.9 M, Fig. 5C) suggesting a
different extent of sulfation.
Together the data suggest that binding of natural HS
saccharides to both Slit and Robo fragments and their ability
to stimulate a Slit-dependent biological response is not simply
dependent on the degree of sulfation (as indicated by the
concentration of NaCl for elution). Diﬀerential binding was
observed for the two proteins. Furthermore, it appears that the
relationship between binding and activity is again quite complex,
with a couple of biologically active saccharide fractions (10F and
10S) binding poorly, at best, to either of the proteins and two
other active saccharide fractions (10I and 8F) binding strongly to
only one or other of the proteins.
Conclusion
Previously, Slit and Robo interactions have been studied separately
using only a few chemically-modified heparin polysaccharides
exhibiting limited structural diversity.19,20,25 As it is diﬃcult
to compare across studies, the investigation of dSlit and dRobo
binding by our study in parallel, using the same assays and
compounds, enables direct comparison to be made for the first
time. In our study Slit and Robo fragments displayed diﬀerent
binding characteristics. In general the dRobo fragment had a
greater preference for binding to heparin than the dSlit frag-
ment, as dRobo bound unmodified heparin more strongly and
removal of sulfates from single positions reduced binding to a
greater extent. Furthermore, the profiles for the binding of each
protein to selected 8-mer and 10-mer PMHS fractions diﬀered,
especially as only a single diﬀerent fraction bound strongly to
either dSlit (10I) or dRobo (8F). Together these observations
suggest that the ligand and receptor exhibit subtle diﬀerences
in their preferences for structural characteristics of partner HS
saccharides. This subtle diﬀerence in ligand and receptor
binding could be significant, as in the case of the fibroblast
growth factor (FGF) system where FGF ligand and FGF receptor
binding to heparin/HS have been shown to be distinct.37
Furthermore, as there are diﬀerent isoforms of Robo, selectivity
for binding to Robo could be important, as is the case for the
FGF system in which diﬀerent HS/receptor interactions occur28
and aﬀect the output of FGF signalling.38
Comparing chemically-modified heparins across individual
protein binding and cellular activity assays suggests that removing
sulfates from two or more positions within the disaccharide
repeats has a substantial eﬀect. The data for removal of sulfates
from a single position within disaccharide repeats are more
complex in that they show a reasonable influence on protein
binding but not on growth cone collapse activity. Similarly,
diﬀerences are seen between HS saccharide profiles for protein
binding compared with cellular activity. These indicate that
there is no simple direct correlative relationship between
protein binding and cellular activity. This probably reflects
the requirement for formation of a ternary complex10 with a
particular architecture, which binding to a single ligand or
receptor protein alone does not resemble. Similar observations
have again been made for the FGF system.39,40
Overall, our results suggest that structural diversity within
HS GAGs aﬀects the Slit–Robo system thus there is clearly
potential for biological regulation of the Slit–Robo system via
variations in HS structure. This proposal is supported by
knockout studies in C. elegans and mice12,16,36 and is also
observed for FGF signalling.41 Further studies (for example
using a collection of pure, structurally-defined HS saccharides)
should help to elucidate such mechanisms.
Experimental
All common chemicals used were of analytical grade and purchased
from VWR (Lutterworth, UK) unless otherwise stated. Porcine
mucosal heparin (PMH) was purchased from Celsus Laboratories
(Ohio, USA). Chemically-modified PMH polysaccharides were pre-
pared and structurally characterised as formerly described.42 PMHS
was a gift from Organon (Oss, Netherlands). All polysaccharides
were quantified by weighing. Recombinant heparinases I, II and III
from Flavobacterium heparinum were purchased from IBEX
(Montreal, Canada); 1 IU is defined as the amount of enzyme that
will liberate 1 mmol of unsaturated oligosaccharides from HS per
minute at 30 1C and pH 7.5. His6-myc-tagged dSlit D1–4 and dRobo
Ig1–5-IgG1Fc proteins were prepared and quantified, using absor-
bance at l = 280 nm and molar extinction coefficients calculated
from sequence, as previously described.10 Molecular weights were
estimated from sequence asB103.5 and 80 KDa, respectively.
Generation of PMHS saccharide chromotographic fractions for
screening
PMHS saccharide fractions were generated using enzymatic
cleavage and chromatographic procedures.24 PMHS (50 mg) was
partially digested with 0.1 mU mg1 (5 mU ml1) of heparinase
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III for 2 h, adding a further 10 mU heparinase III and then
again at 24 hours, before heating to 100 1C. Heparinase-
generated saccharide mixtures were first separated by hydro-
dynamic volume using SEC with a Superdext 30 (GE Healthcare,
UK) column (16 mm I.D.  200 cm length) performed in 0.5 M
ammonium hydrogen carbonate at a flow rate of 0.5 ml min1.
Peak fractions were collected and desalted using a HiPrept 26/10
Desalting column (GE Healthcare, UK) in water at 5 ml min1
and concentrated using freeze drying. Selected SEC fractions were
further separated by charge using high resolution, SAX-HPLC. For
this procedure, a 9  250 mm Propac PA1 column (Dionex, UK)
was equilibrated in double deionised water (pHB 3.5) at a flow
rate of 1 ml min1. Sample (B3 mg) was then loaded onto the
column in water (BpH 3.5) before elution with a linear gradient
of sodium chloride (0–1 M, BpH 3.5 over 180 min), monitoring
absorbance at l = 232 nm for fraction collection. Multiple
separations were performed and replicate fractions of peaks were
pooled and desalted using the HiPrept 26/10 Desalting column
run in water at 5 ml min1 and then concentrated using freeze
drying. SEC and desalting chromatography was performed using
an AKTA purifier 10 (GE Healthcare), whilst SAX-HPLC used a
Shimadzu HPLC with SCL-10A controller, LC-10AT pump,
CS16150 vacuum degasser, FCV-10AL mixer, CTO-10 AS column
oven, SPD-10 UV detector and Class-VP chromatography data
system (Shimadzu, UK).
Saccharides in SEC fractions were quantified by weighting
following lyophilisation as large amounts of saccharide were
available (Z1 mg). The concentrations of saccharides in SAX-
HPLC fractions were quantified using absorbance at l = 232 nm
and the molar extinction coeﬃcient of 5500 mol1 cm1 for
the unsaturated bond chromophore generated by heparinase
enzymes.43 Molecular weights of diﬀerent sized saccharides
were estimated using 440 Da per disaccharide.
Generation of biotinylated heparin B10-mer SEC fraction
saccharides
PMH saccharide mixtures were generated using nitrous acid
cleavage.44 Nitrous acid (pHB 2.0) was freshly made by adding
0.5 M sodium nitrite to an equal volume of 0.5 M hydrochloric
acid and the mixture kept on ice. An equal volume of the 250 mM
nitrous acid solution was used to dilute 100 mg ml1 heparin at
room temperature before removing aliquots at 10, 20, 30 and
40 minutes and stopping the digestion by neutralisation with
1 M sodium hydrogen carbonate. Saccharide mixtures were then
separated using the Superdext 30 SEC column as described
above. For biotinylation, lyophilisedB10-mer fraction was dissolved
at 10 mg ml1 in double deionised water (BpH 5.0 using HCL). A
five-foldmolar excess of 2.5mM aminoxybiotin [N-(aminooxyacetyl)-
N0-(D-biotinoyl) hydrazine, trifluoroacetic acid salt (ARP)] (Invitrogen,
UK) in double deionised water was added and the reaction mixture
incubated for aminimum of 16 hours at 50 1C. Sequential runs over
a 0.5 ml DEAE-Sephacel (GE Healthcare) column were used to
remove free biotin reagent. The DEAE column was equilibrated
with 50 mM NaCl/10 mM phosphate buﬀer (pH 7.0), the sample
was loaded and washed with buﬀer to remove unreacted biotin
(B50 column volumes), before eluting bound oligosaccharides
with 1 ml of 2 M NaCl. Absorbance of eluted fractions was
monitored at l = 232 nm using a spectrophotometer (Shimadzu,
UK). Elution fractions were pooled and desalted using the HiPrept
26/10 Desalting column. Biotinylation of the B10-mer saccharide
fraction was confirmed using a dot blot with a nitrocellulose
membrane (Hybond-ECL, GE Healthcare, UK), blocking with 5%
(w/v) BSA and probing with an anti-biotin-HRP fusion protein
(Cell Signalling, UK).
ELISAs
ELISAs were used to study HS-protein interactions.28 Streptavidin
(3 mg ml1; Promega, UK) in 0.1 M sodium carbonate/sodium
hydrogen carbonate was incubated for 16 hours at 4 1C in
Maxisorp 96-well microtiter plates (Nunc, UK). Plates were
blocked with 1% (w/v) BSA in PBS for 2 hours at room
temperature and washed with PBS, 0.05% (v/v) Tween 20
(Sigma, UK) (PBST), before incubation with the biotinylated
PMH B10-mer SEC fraction saccharides in 1% (w/v) BSA/PBST
for 2 hours at room temperature and further washing with
PBST. For protein dose experiments, wells were incubated with
varying concentrations of his6-myc-tagged dSlit D1–4 and
dRobo Ig1–5-Fc in 1% BSA, PBST overnight at 4 1C. Alterna-
tively, for competition ELISA experiments, fixed concentrations
of dSlit D1–4 (60 mg ml1: B55% of maximal binding to the
immobilised PMH B10-mer: Fig. 3A) and dRobo Ig1–5-Fc
(30 mg ml1: B75% of maximal binding to the immobilised
PMHB10-mer: Fig. 3A) were incubated under the same conditions
with varying concentrations of polysaccharides. For oligosaccharide
competition, the fixed concentrations of proteins detailed above
were incubated with saccharide fractions, at concentrations that
varied (for dose-determination using SEC fractions: ESI,† Page S6)
or that were fixed (for screening of SAX fractions at 100 mg ml1,
corresponding to B50% or B25% competition of Slit and Robo
binding by a PMH B10-mer SEC fraction, respectively: ESI,†
Page S6). For dSlit D1–4 detection, mouse anti-myc (9E10) antibody
(Sigma, UK) was added at 1 mg ml1 and then sheep anti-mouse
IgG-horse radish peroxidise (HRP) (GEHealthcare, UK) at 1 mgml1.
dRobo Ig1–5-Fc detection used a goat anti-human IgG-HRP
conjugate (Fisher Scientific, UK) at 0.2 mg ml1. All antibodies
were incubated in 1% BSA, PBST for 1 hour at room temperature.
Antibody binding was detected using a solution of the HRP
substrate (orthophenylenediamine) by following the manufac-
turer’s instructions (Dako, UK) and measuring product absorbance
at l = 492 nm (A492) using a plate reader (Thermo, UK). A492 values
were exported to Microsoft Excel 2010 and further calculations
performed: to account for variance between plates in the HRP
reaction time, relative% binding of proteins to polysaccharides or
saccharide fractions were calculated using the formula: 100 
[(mean A492 in the presence of competitor/mean A492 in the absence
of competitor) 100]. Combined standard deviations for relative%
binding were calculated using the formula SE = 100  [Avx/Avy
O{(SDx2/Avx)2 + (SDy2/Avy)2}  100], where x is A492 in the presence
of competitor and y is A492 in the absence of competitor, Av is the
mean value and SD the standard deviation. Graphs were generated
using SigmaPlot V11 and, where appropriate, EC50s were calculated
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using non-linear regression with a 4-parameter logistic equation
with the software, giving R2 values of 0.99–1.
Retinal axon growth cone collapse bioassay
Chick retina axon-growth-cone collapse assays were used to
measure the activity of dSlit D1–4.31 For stage one, cover-slips
(VWR, UK) were sterilized by oven heat and then coated with
70 ml 10 mg ml1 sterile poly-L-lysine (Sigma, UK) in 100 mM
sodium borate buffer pH 8.3 (Sigma, UK) for 1 hour. After
incubation, the cover-slips were washed by dipping twice into
HBSS medium (Invitrogen/Gibco, UK). Cover-slips were then
coated with 30 ml of 10 mg ml1 sterile laminin (Invitrogen, UK)
in double deionised water and incubated for 1 h at room
temperature. They were washed again by dipping into HBSS
and placed into 4-well plates (Nunc/VWR, UK) with their coated
side facing up. Each well was covered with 0.5 ml of retina
culture medium [Hams F12 glutamax (Invitrogen/Gibco, UK),
0.5% (w/v) methylcellulose (Sigma, UK), 100 units per ml
penicillin/streptomycin (Invitrogen/Gibco, UK), 5 mg ml1
transferrin/insulin/selenium (Invitrogen/Gibco, UK), 100 mg ml1
transferrin (Sigma, UK) and 100 mg ml1 BSA (Sigma, UK)]. The
4-well plates were incubated at 37 1C until required.
The second stage was started by removing whole eyes from
several E7 chick embryos. E7 chick embryos do not come under
home oﬃce legislation and do not require ethical approval.
These eyes were placed in Ham’s F12 medium for 5 minutes at
37 1C which helps in the dissection step. All the subsequent
steps in this stage were performed in Ham’s medium and
under sterile conditions. Dissection of each eye was started
by removal of connective tissue (the whitish layer surrounding
the eye), and followed by removal of the retinal pigmented
epithelium (the dark brown or black layer). Finally, the lens was
removed with the vitreous humor (gelatinous ball) attached. It
was observed that retina began to curl after several minutes in
medium. Retina extracted from the group of eyes, which were
deemed suitable for use, were then cut into pieces of the required
size (B1 mm  1 mm) using dissecting scissors. These pieces
were then transferred to coverslips (3–4 pieces on each coverslip)
and incubated in medium at 37 1C for 24 hours.
For the third stage, pieces of retina were checked for the
growth of well-defined axon growth cones using an inverted
microscope. Unsuitable pieces of retina were discarded. Pieces
of retina were incubated at 37 1C for three hours in 500 ml of retina
culture medium in the presence or absence of heparinases I, II
and III (each added at 5 mU ml1) as appropriate. This medium
was then replaced with concentrations of dSlit D1–4 in PBS. To
screen for the effect of GAGs, 10 mg ml1 dSlit D1–4 (B90% of
maximal activity: ESI,† Page S7) was added in the presence
or absence of polysaccharides and oligosaccharide fractions at
concentrations that varied (dose identification: ESI,† Page S7) or
that were fixed (200 mg ml1 polysaccharide:B90% of maximum
activity of PMH or 50 mg ml1 oligosaccharide fraction:B65% of
maximum activity of a B10-mer PMH SEC fraction, ESI,†
Page S7). Solutions were incubated for 20 minute at 37 1C.
For the final stage, cover-slips were fixed by gently adding
250 ml of fixing medium (0.12 M sucrose, 0.5 mM CaCl2, 75 mM
Millonig’s Phosphate Buﬀer, 2% glutaraldehyde) (Sigma, UK) on
one side of the well followed by incubation for 30 min at room
temperature. Cover-slips were lifted up oﬀ the wells and washed
twice with double deionised water, air dried at room temperature
and mounted on a glass slide (two cover-slips per slide). PBS
was found to be the best mounting solution (as many other
commercially-available mounting solutions failed, due to the pro-
blem of air bubbles under the cover-slips making it diﬃcult to
properly assess themorphology of the growth cones). The cover slip
was sealed around the edges using clear nail varnish. A Zeiss LSM
510 Meta microscope with LSM 510 software was used to count
collapsed and uncollapsed growth cones across several pieces of
retina until 80–110 axons had been assessed. Average and standard
deviation values for % collapse across coverslips with replicate
groups of slices from the retinal pool were calculated using
Microsoft Excel 2010 and graphs generated using Sigma Plot V11.
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